Cellectar Biosciences

+$0.038 (+10.80%) Today
+$0.0268 (+6.87%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CLRB and other ETFs, options, and stocks.

About CLRB

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination.

CEO
James V. Caruso
Employees
12
Headquarters
Florham Park, New Jersey
Founded
1996

CLRB Key Statistics

Market cap
23.97M
Price-Earnings ratio
—
Dividend yield
—
Average volume
157.56K
High today
$0.4423
Low today
$0.3401
Open price
$0.3503
Volume
203.72K
52 Week high
$1.84
52 Week low
$0.3401

CLRB Earnings

-$0.20
-$0.13
-$0.07
$0.00
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 8, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure